Clinical Trial

SMP-3124LP in Adults With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-07-24; most recent amendment 2026-02-25.
Status change: Not Yet Recruiting → Recruiting 2024-09-03
Trial Details
NCT Number NCT06526819
Lead Sponsor Sumitomo Pharma America, Inc.
Conditions Solid Tumor
Enrollment 120 participants
Start Date 2024-08-14
Primary Completion 2028-12 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-12